DTaP-Hib vaccine explained
DTaP-Hib vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed with Haemophilus B conjugate vaccine, sometimes abbreviated to DTaP-Hib.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.[2]
A branded formulation was marketed in the US as TriHIBit by Sanofi Pasteur, and administered by using the Sanofi DTaP vaccine Tripedia to reconstitute the Sanofi Hib vaccine ActHIB.[2] [3] [4] TriHIBit and Tripedia were discontinued in 2011.[5]
See also
Notes and References
- Web site: Trihibit (diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / tetanus toxoid) Disease Interactions. 15 July 2018. Drugs.com.
- Web site: Notice to Readers FDA Approval of a Haemophilus b Conjugate Vaccine Combined by Reconstitution with an Acellular Pertussis Vaccine. Centers for Disease Control and Prevention. 15 July 2018. Morbidity and Mortality Weekly Report. 45. 45. 993–995. 15 November 1996.
- Web site: https://wayback.archive-it.org/7993/20170112211659/http:/www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM101580.pdf. 12 January 2017. Tripedia package insert. dead. US Food and Drug Administration. 15 July 2018.
- Web site: ActHIB package insert. US Food and Drug Administration. 15 July 2018.
- Web site: Selected Discontinued U.S. Vaccines. Centers for Disease Control and Prevention. 15 July 2018.